AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in this application.

LISTING OF CLAIMS:

1-69 (Canceled).

70. (New) A method for producing a paramunity inducer, comprising:

(a) isolating a myxomavirus from infected tissue of a rabbit;

(b) adapting the virus to a permissive cell system; and

(c) passaging the adapted virus in a binary cell culture obtained by cell fusion of two cell types to generate an attenuated myxomavirus that induces paramunity.

71. (New) The method of claim 70, wherein the adaptation of the virus to a permissive cell system comprises culturing the virus on a chorioallantoic membrane of an incubated chicken egg.

72. (New) The method of claim 70, wherein the passaging of the adapted virus comprises passaging the virus in Vero monkey kidney cells.

73. (New) The method of claim 72, wherein the virus is passaged at least 80 passages in Vero monkey kidney cells.

74. (New) The method of claim 73, wherein the virus is passaged at least 120 passages in Vero monkey kidney cells.

75. (New) The method of claim 74, wherein the virus is passaged at least 150 passages in Vero monkey kidney cells.

76. (New) The method of claim 70, wherein the binary cell culture is an AVIVER cell culture obtained by cell fusion between chicken embryo fibroblast cells and Vero monkey kidney cells.

77. (New) The method of claim 76, wherein the virus is passaged at least 10 passages in the AVIVER cell culture.

78. (New) The method of claim 77, wherein the virus is passaged at least 25 passages in the AVIVER cell culture.

79. (New) The method of claim 78, wherein the virus is passaged at least 50 passages in the AVIVER cell culture.

80. (New) The method of claim 70, wherein the attenuated myxomavirus is inactivated with beta-propiolactone.

81. (New) The method of claim 80, wherein the beta-propiolactone is at a concentration of 0.01%-1%.

82. (New) A method for producing a paramunity inducer, comprising:

(a) isolating a myxomavirus from infected tissue of a rabbit;

(b) adapting the virus to a permissive cell system; and

(c) passaging the adapted virus to generate an attenuated myxomavirus that induces paramunity, wherein the attenuated myxomavirus has lost the receptor properties of one or more myxomavirus interferon receptor, one or more myxomavirus tumor necrosis factor receptor, and one or more myxomavirus interleukin receptor.

83. (New) The method of claim 82, wherein the attenuated myxomavirus has lost the receptor properties of the myxomavirus cytokine receptors IFNα-R, IFNγ-R, TNF-R, IL-1-R, IL-2-R, IL-6-R, and IL-12-R.

84. (New) The method of claim 82, wherein the adaptation of the virus to a permissive cell system comprises culturing the virus on a chorioallantoic membrane of an incubated chicken egg.

85. (New) The method of claim 82, wherein the passaging of the adapted virus comprises passaging the virus in Vero monkey kidney cells.

86. (New) The method of claim 85, wherein the virus is passaged at least 80 passages in Vero monkey kidney cells.

87. (New) The method of claim 86, wherein the virus is passaged at least 120 passages in Vero monkey kidney cells.

88. (New) The method of claim 87, wherein the virus is passaged at least 150 passages in Vero monkey kidney cells.

89. (New) The method of claim 82, wherein the virus is passaged in a binary cell culture obtained by cell fusion of two cell types.

90. (New) The method of claim 89, wherein the virus is passaged in an AVIVER cell culture obtained by cell fusion between chicken embryo fibroblast cells and Vero monkey kidney cells.

91. (New) The method of claim 90, wherein the virus is passaged at least 10 passages in the AVIVER cell culture.

92. (New) The method of claim 91, wherein the virus is passaged at least 25 passages in the AVIVER cell culture.

93. (New) The method of claim 92, wherein the virus is passaged at least 50 passages in the AVIVER cell culture.